Bayer Pulls Remaining Trasylol From U.S. Market
Bayer HealthCare Pharmaceuticals Inc. had opted to remove the remaining stock from warehouses and hospitals as lawsuits over the medication trickle into the courts, the U.S. Food and Drug Administration announced Wednesday.
“The FDA will work with Bayer to ensure a smooth and complete process,” the agency said.
At the FDA's urging, Bayer suspended...
To view the full article, register now.